Preliminary Trial of SNA014 for Pancreatic Cancer

A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET/CT for the Imaging of Pancreatic Cancer

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer

Inclusion Criteria:

1. Aged between 18 and 75 years (inclusive);
2. Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);
3. Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
4. Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
5. Pathology test results from within the past year;

Exclusion Criteria:

1. Patients with other clearly diagnosed malignant tumours;
2. Patients with uncontrolled severe infections, or those with other serious comorbidities;
3. Patients with a life expectancy of ≤3 months;
4. Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;
5. Patients deemed unsuitable for participation in this study by the investigator.